Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Evogene logo — Real-World Innovation. Pioneering chemical Discovery with Ge...

Evogene

Real-World Innovation. Pioneering chemical Discovery with Generative AI

Founded 2002 Israel Israel 103 employees Post-IPO Equity Total: $106.20M Agriculture, Biotechnology

General Information

Company Name Evogene
Founded Year 2002
Location Israel Israel
Employees 103
Industries Agriculture, Biotechnology
Funding Stage Post-IPO Equity
Business Model B2B, Platform, B2B2B
Revenue Model Licensing, Project Based, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Evogene. To contact Evogene, visit evogene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Evogene

Evogene Ltd. (Nasdaq/TASE: EVGN) is a trailblazer in the realm of computational chemistry, leveraging its expertise to design small molecules for the pharmaceutical and agricultural sectors. Founded in 2002 and headquartered in Israel, the company operates at the intersection of Agriculture and Biotechnology industries.

At the heart of Evogene's technological prowess lies ChemPass AI, a groundbreaking generative AI engine. This proprietary platform excels at crafting novel, potent small molecules, optimizing them across vital parameters to bolster success rates while slashing development time and costs.

In a strategic move, Evogene recently secured an $8.50M Post-IPO equity investment on July 17, 2023, backed by prominent investors including Altium Capital, Silverarc Capital, and CVI Investments. This strategic funding underscores the company's commitment to integrating scientific innovation with tangible industry applications, embracing what they term as "Real-World Innovation."

Taxonomy: Computational Chemistry, Generative AI, Small Molecule Design, Pharmaceutical Industry, Agricultural Industry, ChemPass AI, Ag-Biotech, Trait Development, Plant Genomics, Seed Traits, Breeding Methods, Crop Performance, Drug Discovery, Life-Science Innovation

Services & Products

Generative AI for Molecule Design
AI-Driven Drug Discovery
Next-Generation Crop Protection
Collaborative Innovation with Partners

Target Customers

Pharmaceutical Companies Agriculture Industry Biotech Researchers Healthcare Innovators

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $8.50M 3
Altium Capital Silverarc Capital
Altium Capital, Silverarc Capital +1
17 Jul 2023
Grant €1.20M 1
European Union
European Union
09 May 2023
Post IPO Equity $10.00M 2
Ark Invest
Ark Invest, Alpha Capital Anstalt
01 Sep 2020
Post IPO Equity $74.00M 1
Monsanto
21 Nov 2013
Private Equity Round $2.00M 1
Aquagro Fund LP
Aquagro Fund LP
30 Apr 2008
Venture Round $7.00M -
01 Mar 2006
Debt Financing $1.50M -
24 Feb 2004
Venture Round $2.00M 1
Binder & Partners Ventures
13 Jan 2003

Evogene Alternatives & Competitors

View All Alternatives
Evogene vs
Solynta | true potato seeds
Solynta | true potato seeds The Netherlands

Unlocking the True Potential of Potatoes

Series C
94 employees
Agriculture, Biotechnology
Evogene vs
Starfield Crop Science
Starfield Crop Science India

Breeding research of various crops to develop and market hybrid and open-pollinated seeds.

2 employees
Agriculture, Biotechnology
Evogene vs
Green World Genetics Sdn Bhd
Green World Genetics Sdn Bhd Malaysia

R&D tropical hybrid seeds company

150 employees
Agriculture, Biotechnology
View all alternatives

FAQ About Evogene

Real-World Innovation. Pioneering chemical Discovery with Generative AI
Evogene was founded in 2002.
Evogene is headquartered in Israel.
Evogene operates in Agriculture and Biotechnology. Its work centres on Computational Chemistry, Generative AI, Small Molecule Design and Pharmaceutical Industry. Its customers include Pharmaceutical Companies, Agriculture Industry and Biotech Researchers.
Evogene has a B2B, Platform and B2B2B business model. Its revenue comes from Licensing, Project Based and Performance Based.
Evogene has approximately 103 employees.
Evogene has completed 8 funding rounds, raising a total of $106.20M. The latest funding stage is Post-IPO Equity.
Evogene offers: Generative AI for Molecule Design, AI-Driven Drug Discovery, Next-Generation Crop Protection, Collaborative Innovation with Partners.
Top alternatives and competitors to Evogene include Solynta | true potato seeds, Starfield Crop Science, Green World Genetics Sdn Bhd, GreenLight Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Evogene and Solynta | true potato seeds are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Evogene, https://bouncewatch.com/company/evogene, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes